Moderna - COVID-19
- Funded by Coalition for Epidemic Preparedness Innovations (CEPI)
- Total publications:1000 publications
Grant number: N/A
Grant search
Key facts
Disease
COVID-19start year
2020Known Financial Commitments (USD)
$1,000,000Funder
Coalition for Epidemic Preparedness Innovations (CEPI)Principal Investigator
N/A
Research Location
United States of AmericaLead Research Institution
ModernaResearch Priority Alignment
N/A
Research Category
Vaccines research, development and implementation
Research Subcategory
N/A
Special Interest Tags
Innovation
Study Type
Unspecified
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
OSLO, NORWAY. Jan 23, 2020 - CEPI, the Coalition for Epidemic Preparedness Innovations, today announced the initiation of three programmes to develop vaccines against the novel coronavirus, nCoV-2019. The programmes will leverage rapid response platforms already supported by CEPI as well as a new partnership. The aim is to advance nCoV-2019 vaccine candidates into clinical testing as quickly as possible. The nCoV-2019 vaccine development efforts will build on existing partnerships with Inovio (Nasdaq: INO) and The University of Queensland (located in Brisbane, Australia). In addition, CEPI today announces a new partnership with Moderna, Inc., (Nasdaq: MRNA) and the U.S. National Institute of Allergy and Infectious Diseases. All of these are pioneering technologies designed to speed up the development of vaccines against emerging threats such as nCoV-2019.
Publicationslinked via Europe PMC
Last Updated:2 hours ago
View all publications at Europe PMC